Skip to content

Microdosing research published in 2026

Page 2 of 3: studies 21 to 40 of 50, newest first. Back to the microdosing overview

Studies

Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi‐Dose Pens

Obesity June 4, 2026 Abigail B. Lodrigues, Alissa V. Russell, Shelby Tungate Lopez et al.

A.M.K. has received advisory/consulting fees from Camurus Pharmaceuticals, Dexcom Inc., Eli Lilly and Company, and Lexidrug/Wolters-Kluwer. A.B.L., A.V.R., and S.T.L. declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.

DOI: 10.1002/oby.70253 (opens in new tab) Macro Reliability semiconductor Medline

Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series

Frontiers in Pharmacology June 3, 2026 Burton J. Tabaac, Robin Carhart-Harris, Teresa Yung

Background: Traumatic brain injury (TBI) can result in prolonged post-concussive syndrome and chronic hypoxic-ischemic brain injury (HIBI) sequelae remains therapeutically challenging with the persistence of significant neurological and cognitive impairments. While conventional treatments often provide limited relief, emerging research explores alternative therapeutic interventions, including...

DOI: 10.3389/fphar.2026.1840956 (opens in new tab) Traumatic brain injury Mood Therapeutic effect Depression economics +6

Street Pharmacology: The Mechanistic Basis of Clinical Pharmacology Underlying the Microdosing Method of Buprenorphine–Naloxone With a Focus on the Unhoused Population

The Journal of Clinical Pharmacology June 1, 2026 David F. Lehmann, Olivia Tanner, Eliesha Pepple et al.

Expanded use of buprenorphine-naloxone use, particularly for marginalized communities, such as the unhoused, is an established priority. Unfortunately, due to fear of the precipitation of opioid withdrawal, this goal remains unmet. In response, microdosing methods during the initial week of treatment do not require opioid abstinence and do not precipitate withdrawal. This review establishes the...

DOI: 10.1002/jcph.70213 (opens in new tab) Full text (opens in new tab) Clinical pharmacology Abstinence Population Clinical trial +4

U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey.

Rand health quarterly June 1, 2026 Michelle Priest, Beau Kilmer, Ben Senator et al.

An increasing number of U.S. states are implementing or considering alternative policies to the prohibition of some psychedelic substances for nonclinical purposes. The authors present new data and analysis to inform these discussions with survey results on the use of 11 psychedelic substances and detailed information about the prevalence of microdosing (i.e., taking a fraction of a full dose,...

The use of drug checking legislation to facilitate illicit drug consumption research: psychedelic microdosing as a case example

Drugs, Habits and Social Policy May 27, 2026 Estelle Miller, David B Menkes, Suresh Muthukumaraswamy et al.

Purpose Current laws prohibiting access to illicit drugs contribute to drug harms as manufacturers and distributors of illicit substances have variable influence over drug supply and quality. Legislation introduced in New Zealand (NZ) in 2021 aimed to address such harm by enabling licenced drug checking providers to directly analyse samples from consumers. This paper aims to detail the use of...

DOI: 10.1108/dhs-10-2025-0046 (opens in new tab) Cannabis Legislation Microdose Context archaeology +10

The “microdosing” dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions

Journal of the American Association of Nurse Practitioners May 26, 2026 Nicole Trainer

ABSTRACT: The recent resolution of semaglutide and tirzepatide shortages by the US Food and Drug Administration (FDA) has fundamentally altered the regulatory landscape for compounded obesity medications. Despite recent federal pricing agreements to reduce GLP-1 costs, ongoing affordability barriers continue to drive patient desperation, fueling a shift toward unsupervised strategies such as...

DOI: 10.1097/jxx.0000000000001296 (opens in new tab) Patient safety Economic shortage Nurse practitioners Risk management +10

Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT

bioRxiv Preprint Server May 5, 2026 Povilas Tarailis, Inga Griškova-bulanova preprint

Electroencephalographic (EEG) microstates provide a compact framework for characterizing the temporal organization of large-scale brain activity, yet their sensitivity to altered brain states remains insufficiently explored. In this study, we applied broadband and frequency-resolved EEG microstate analysis to resting-state EEG data from two publicly available datasets acquired under markedly...

First-in-human intrapulmonary intratarget microdosing of a novel dual inflammasome inhibitor of NLRP 1/ NLRP 3 in ex vivo human lungs and patients with interstitial lung disease

medRxiv Preprint Server May 5, 2026 Tom M. Quinn, Feng Li, Becky Wheeler et al. preprint

The development of lung-directed therapeutics is limited by poor translational fidelity between preclinical models and early-phase clinical trials. We report a first-in-human Phase 0 intratarget microdosing study demonstrating the feasibility of intrapulmonary delivery and pharmacological interrogation of a novel inflammasome inhibitor. A 100 μg microdose of ADS032, a dual NLRP1/NLRP3...

Microdosing of Flywheel Training: Effects of Low Versus High Training Frequency on Muscle Mass, Strength, and Power.

International Journal of Sports Physiology and Performance May 4, 2026 Sergio Maroto-Izquierdo, Marina Gómez, Susana López-Ortiz et al.

This study compared the effects of low-frequency flywheel resistance training (FRT, 1 session/week) and microdosing FRT (5 sessions/week) on muscle architecture, strength, and vertical jump performance in active individuals. Thirty participants were randomized into a microdosing group (MDG, n = 15) or a control group (CG, n = 15). Both groups completed equalized weekly training volumes (30 sets...

DOI: 10.1123/ijspp.2025-0582 (opens in new tab) Full text (opens in new tab) Eccentric overload Muscle architecture Neuromuscular adaptations Resistance training +1

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults

American Journal of Preventive Medicine May 4, 2026 Kevin H. Yang, Nora Satybaldiyeva, Wayne Kepner et al. 1 citation

IntroductionMicrodosing involves consuming low doses of psychoactive substances, typically between 1/5th and 1/20th of a recreational dose. Despite increasing public attention to cannabis and psychedelics amid evolving drug policies, epidemiologic data on microdosing remain limited.MethodsA cross-sectional, web-based survey (Characterizing the Epidemiology of Cannabidiol Use Survey) of 1,523...

A New Use for an Old Compound: Microdosing LSD to Reduce Fibromyalgia Symptoms

April 17, 2026 Sara Arciniegas Ruiz, Sari Prutchi Sagiv, Hagit Eldar-Finkelman

Fibromyalgia (FM) is a chronic pain condition characterized by widespread pain, fatigue, sleep disturbances, and mood changes. Available treatments often provide limited relief, highlighting the need for new therapeutic approaches. Repurposing offers a faster and more cost-effective path to innovation. Lysergic acid diethylamide (LSD), historically known for its psychedelic effects, has...

Floorless closed-loop microdosing for rail friction: a physics-only digital twin on Kuwait city’s blue corridor

Industrial Lubrication and Tribology April 7, 2026 Abdullah Mohammed

Purpose This study aims to present a lightweight digital twin for top-of-rail (TOR) friction management that relies only on physics and closed-loop control; no artificial “friction floor.” Design/methodology/approach The twin couples along-track film transport (diffusion; diurnal evaporation, curvature-weighted axle consumption, optional rain wash-off) with a monotone, saturating µ(h) map and a...

804. A New Paradigm in Wound Healing: Topical Microdosing Approaches

Journal of Burn Care & Research April 6, 2026 Manuel Prevedel, Maximilian Moshammer, Simon Schwingenschuh et al.

Abstract Introduction Difficult to treat wounds, such as burns and chronic wounds, constitute a continuous challenge. One current trend is towards developing dressings that allow for targeted delivery of active substances. However, some promising substances are hormones and while exerting positive effects on wound healing, systemic distribution may have detrimental effects and are to be...

Psilocybin microdosing in the United States: Insights from a nationally representative survey

Addiction March 8, 2026 Michelle Priest, Beau Kilmer, Rajeev Ramchand et al. 1 citation

At least 8.4 million US adults have microdosed psilocybin in their lifetime. Those who have used psilocybin within the past year are more likely to report microdosing the last time they used than those who have used psilocybin more than one year ago; however, approximately 15% respondents who used psilocybin in their lifetime were unsure whether they microdosed the last time they used....

DOI: 10.1111/add.70368 (opens in new tab) Psilocybin Multinomial logistic regression Epidemiology Microdose +6

Epidemiology of Hallucinogen Microdosing Among Young Adults in the United States: A National Study

Drug and Alcohol Review February 26, 2026 Katherine M Keyes, Yvonne Terry-Mcelrath, Megan E. Patrick

INTRODUCTION: This paper aimed to determine the prevalence, demographic correlates and co-occurring substance use patterns of hallucinogen microdosing among young adults in the United States. METHODS: Design: Cross-sectional analysis of data from a nationally-representative cohort study collected in 2022-2023. SETTING: United States. PARTICIPANTS: Sample of 3094 young adults aged 19-30 years in...

DOI: 10.1111/dar.70133 (opens in new tab) Young adult Context archaeology Epidemiology Drug +3

Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial

Research Square February 23, 2026 Rotem Petranker, Norman A. S. Farb, Omer A. Syed et al. preprint

Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant effects and safety of repeated low doses of psilocybin in participants diagnosed with MDD. DESIGN This was a Phase II, randomized, double-blind, placebo-controlled clinical trial. SETTING The trial was conducted from July 2022 to December 2024 at two...

LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial

Progress in Neuro-Psychopharmacology and Biological Psychiatry February 18, 2026 Dimitri Henriques Daldegan-Bueno, C Donegan, Rachael Sumner et al. 1 citation

Results suggest short-term improvements in mood following microdosed LSD in people with depression, warranting confirmation in controlled trials. It provides the pharmacokinetic parameters of 8 μg of LSD in a sample of people with depression and indicates no tolerance or sensitisation to repeated microdoses of LSD, despite incremental dose titration.

DOI: 10.1016/j.pnpbp.2026.111645 (opens in new tab) Major depressive disorder Pharmacokinetics Depression economics Depressive symptoms +6

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial

BJPsych Open February 16, 2026 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al. 1 citation

BACKGROUND: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...

Exploring a Decade of Microdosing Research: A Qualitative Meta-synthesis of Microdosing Literature

Deviant Behavior February 9, 2026 Blake Beaton 2 citations

Microdosing is a novel approach to the consumption of classic psychedelic substances, such as LSD (lysergic acid diethylamide) and psilocybin that emerged in recent years. Unlike traditional illicit substance use, which often seeks euphoric experiences, microdosing deliberately avoids such effects in pursuit of self-enhancement. This practice has grown in popularity likely due to the perceived...

DOI: 10.1080/01639625.2026.2624690 (opens in new tab) Qualitative research Qualitative analysis Data collection Engineering ethics +3

Technical pen-based printhead for high-precision microdosing of personalized therapies.

Drug delivery and translational research February 6, 2026 Paola Carou-Senra, Carlos Rial, Alex Richter et al.

Additive manufacturing offers unprecedented opportunities for personalized medicine, but most pharmaceutical printing platforms are optimized for milligram-range doses, limiting their suitability for microdosing. This work introduces a novel liquid deposition approach using a modified technical pen integrated into a pharmaceutical printer. The gravity-driven mechanism enabled precise microscale...

DOI: 10.1007/s13346-026-02065-1 (opens in new tab) Full text (opens in new tab) Additive manufacturing Biologics High-precision microdosing Low-dose drug delivery +2